Form 4 for ROIV Roivant Sciences Ltd.

Accepted 2026-09-18 19:01:43 ET · period of report 2026-09-16 · accession 0001209181-26-000007 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-09-18 19:01	2026-09-16	ROIV	MOMTAZEE JAMES C	Dir	A - Grant	$0.00	+5,054	112.0K	+5%	$0
D	2026-09-18 19:01	2026-09-16	ROIV	MOMTAZEE JAMES C	Dir	A - Grant	$0.00	+10.5K	10.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Shares	2026-09-16	A	A	5,054	$0.00	111,959	D	—	—	(F1) Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date. (F1) Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.
2	Derivative	Stock Option (Right to Buy)	2026-09-16	A	A	10,531	$0.00	10,531	D	$39.57 · — to 2036-09-15	10,531 Common Shares	(F2) Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date.